186 related articles for article (PubMed ID: 27884434)
1. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.
Osborn D; Marston L; Nazareth I; King MB; Petersen I; Walters K
Schizophr Res; 2017 May; 183():116-123. PubMed ID: 27884434
[TBL] [Abstract][Full Text] [Related]
2. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.
Osborn DP; Petersen I; Beckley N; Walters K; Nazareth I; Hayes J
J Psychopharmacol; 2018 Oct; 32(10):1098-1103. PubMed ID: 29938561
[TBL] [Abstract][Full Text] [Related]
3. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
Layton D; Harris S; Wilton LV; Shakir SA
J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184
[TBL] [Abstract][Full Text] [Related]
4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark.
Pasternak B; Svanström H; Ranthe MF; Melbye M; Hviid A
CNS Drugs; 2014 Oct; 28(10):963-73. PubMed ID: 24895158
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
7. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
[TBL] [Abstract][Full Text] [Related]
8. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
10. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.
Bobes J; Garc A-Portilla MP; Rejas J; Hern Ndez G; Garcia-Garcia M; Rico-Villademoros F; Porras A
J Sex Marital Ther; 2003; 29(2):125-47. PubMed ID: 12623765
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.
Kilian R; Steinert T; Schepp W; Weiser P; Jaeger S; Pfiffner C; Frasch K; Eschweiler GW; Messer T; Croissant D; Becker T; Längle G
Eur Arch Psychiatry Clin Neurosci; 2012 Oct; 262(7):589-98. PubMed ID: 22526729
[TBL] [Abstract][Full Text] [Related]
12. Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
Hayes JF; Marston L; Walters K; Geddes JR; King M; Osborn DP
PLoS Med; 2016 Aug; 13(8):e1002058. PubMed ID: 27483368
[TBL] [Abstract][Full Text] [Related]
13. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
[TBL] [Abstract][Full Text] [Related]
14. Mortality risk and mood stabilizers in bipolar disorder: a propensity-score-weighted population-based cohort study in 2002-2018.
Chan JKN; Wong CSM; Fang CZ; Hung SC; Lo HKY; Chang WC
Epidemiol Psychiatr Sci; 2024 May; 33():e31. PubMed ID: 38779809
[TBL] [Abstract][Full Text] [Related]
15. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
16. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study.
Chatterjee S; Chen H; Johnson ML; Aparasu RR
Am J Geriatr Pharmacother; 2012 Apr; 10(2):83-94. PubMed ID: 22306198
[TBL] [Abstract][Full Text] [Related]
17. Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.
Chyou TY; Nishtala R; Nishtala PS
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):692-700. PubMed ID: 32301237
[TBL] [Abstract][Full Text] [Related]
18. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
19. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
[TBL] [Abstract][Full Text] [Related]
20. Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study.
Chatterjee S; Chen H; Johnson ML; Aparasu RR
Drugs Aging; 2012 Oct; 29(10):807-17. PubMed ID: 23018582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
